These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1412 related items for PubMed ID: 29276022

  • 21. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A.
    N Engl J Med; 2010 Nov 04; 363(19):1812-21. PubMed ID: 21047225
    [Abstract] [Full Text] [Related]

  • 22. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial.
    Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puverel S, Nwangwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T.
    Lancet Haematol; 2023 Jan 04; 10(1):e14-e23. PubMed ID: 36403579
    [Abstract] [Full Text] [Related]

  • 23. Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma.
    Koga Y, Sekimizu M, Iguchi A, Kada A, Saito AM, Asada R, Mori T, Horibe K.
    Int J Hematol; 2020 May 04; 111(5):711-718. PubMed ID: 31960285
    [Abstract] [Full Text] [Related]

  • 24. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
    Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L, ECHELON-2 Study Group.
    Lancet; 2019 Jan 19; 393(10168):229-240. PubMed ID: 30522922
    [Abstract] [Full Text] [Related]

  • 25. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
    Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J, ECHELON-1 Study Group.
    N Engl J Med; 2018 Jan 25; 378(4):331-344. PubMed ID: 29224502
    [Abstract] [Full Text] [Related]

  • 26. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.
    Haddley K.
    Drugs Today (Barc); 2012 Apr 25; 48(4):259-70. PubMed ID: 22536568
    [Abstract] [Full Text] [Related]

  • 27. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC, Czuczman M, Salles G, Assouline S, Sehn LH, Flinn I, Patel MR, Sangha R, Hagenbeek A, Advani R, Tilly H, Casasnovas O, Press OW, Yalamanchili S, Kahn R, Dere RC, Lu D, Jones S, Jones C, Chu YW, Morschhauser F.
    Lancet Oncol; 2015 Jun 25; 16(6):704-15. PubMed ID: 25925619
    [Abstract] [Full Text] [Related]

  • 28. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL, Figgitt DP.
    Drugs; 2003 Jun 25; 63(8):803-43. PubMed ID: 12662126
    [Abstract] [Full Text] [Related]

  • 29. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
    Sekimizu M, Iguchi A, Mori T, Koga Y, Kada A, Saito AM, Horibe K.
    BMC Cancer; 2018 Feb 01; 18(1):122. PubMed ID: 29390984
    [Abstract] [Full Text] [Related]

  • 30. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
    Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R.
    J Clin Oncol; 2012 Jun 20; 30(18):2183-9. PubMed ID: 22454421
    [Abstract] [Full Text] [Related]

  • 31. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
    Wagner SM, Melchardt T, Egle A, Magnes T, Skrabs C, Staber P, Simonitsch-Klupp I, Panny M, Lehner B, Greil R, Keil F, Jäger U, Sillaber C.
    Eur J Haematol; 2020 Mar 20; 104(3):251-258. PubMed ID: 31838747
    [Abstract] [Full Text] [Related]

  • 32. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M, HELIOS investigators.
    Lancet Oncol; 2016 Feb 20; 17(2):200-211. PubMed ID: 26655421
    [Abstract] [Full Text] [Related]

  • 33. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma.
    Picardi M, Della Pepa R, Giordano C, Pugliese N, Mortaruolo C, Trastulli F, Rascato MG, Cappuccio I, Raimondo M, Memoli M, Monteverde M, Mascolo M, Pane F.
    Blood Adv; 2019 May 14; 3(9):1546-1552. PubMed ID: 31088808
    [Abstract] [Full Text] [Related]

  • 34. Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma.
    Vinti L, Pagliara D, Buffardi S, Di Ruscio V, Stocchi F, Mariggiò E, Parasole R, Di Matteo A, Petruzziello F, Paganelli V, De Vito R, Del Bufalo F, Strocchio L, Locatelli F.
    Pediatr Blood Cancer; 2022 Apr 14; 69(4):e29557. PubMed ID: 35107876
    [Abstract] [Full Text] [Related]

  • 35. Brentuximab vedotin for the treatment of CD30+ lymphomas.
    Foyil KV, Bartlett NL.
    Immunotherapy; 2011 Apr 14; 3(4):475-85. PubMed ID: 21463188
    [Abstract] [Full Text] [Related]

  • 36. Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program.
    Perrot A, Monjanel H, Bouabdallah R, Quittet P, Sarkozy C, Bernard M, Stamatoullas A, Borel C, Bouabdallah K, Nicolas-Virelizier E, Fournier M, Morschhauser F, Brice P, Lymphoma Study Association (LYSA).
    Haematologica; 2016 Apr 14; 101(4):466-73. PubMed ID: 26768687
    [Abstract] [Full Text] [Related]

  • 37. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma.
    Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, Cho S, Wu Y, Punnett A, Dave H, Henderson TO, Hoppe BS, Charpentier AM, Keller FG, Kelly KM.
    N Engl J Med; 2022 Nov 03; 387(18):1649-1660. PubMed ID: 36322844
    [Abstract] [Full Text] [Related]

  • 38. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R, Blonquist TM, Emadi A, Hasserjian RP, Burke M, Lescinskas C, Neuberg DS, Brunner AM, Hobbs G, Hock H, McAfee SL, Chen YB, Attar E, Graubert TA, Bertoli C, Moran JA, Bergeron MK, Foster JE, Ramos AY, Som TT, Vartanian MK, Story JL, McGregor K, Macrae M, Behnan T, Wey MC, Rae J, Preffer FI, Lesho P, Duong VH, Mann ML, Ballen KK, Connolly C, Amrein PC, Fathi AT.
    Cancer; 2020 Mar 15; 126(6):1264-1273. PubMed ID: 31860140
    [Abstract] [Full Text] [Related]

  • 39. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
    Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, Popplewell L, Siddiqi T, Thomas SH, Mott M, Sahebi F, Armenian S, Leonard J, Nademanee A, Forman SJ.
    Biol Blood Marrow Transplant; 2015 Dec 15; 21(12):2136-2140. PubMed ID: 26211987
    [Abstract] [Full Text] [Related]

  • 40. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
    Terriou L, Bonnet S, Debarri H, Demarquette H, Morschhauser F.
    Bull Cancer; 2013 Dec 15; 100(7-8):775-9. PubMed ID: 23831822
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 71.